New insights into Pre-RA: It ranges from asymptomatic individuals with ACPA positivity to those with symptomatic pre-clinical synovitis. Predicting who will develop RA is difficult, and there is a need for reliable biologic tools. Focusing on high-risk patients could https://t.co/SPOP7f0t7y

When every option fails, bold moves remain. In 5 multi-resistant RA pts, TNFi + JAKi combo brought remission in most without major AEs. Not standard, not risk-free, but in young, low-infection-risk pts, it may offer a path forward. @RheumNow #ACR25 Abstract#2272

Post hoc eval of relapses from MANDARA, MEPO vs BEN in EGPA 30% of pts had relapse, 81% of which were asthma +/- sinonasal disease Remainder were mostly muscle involved, only a few mononeuritis Mostly as expected; useful epi data for clinic #ACR25 @RheumNow Abstr#1769 https://t.co/IKKolMZJlF

• https://x.com/EBRheum/status/1983209393299619853/photo/1
• https://x.com/EBRheum/status/1983209393299619853/photo/1
• https://x.com/EBRheum/status/1983209393299619853/photo/1

Late Breaker: Phase 2 RCT of low dose IL2 in SLE Dose dependent response in SRI4 over 12 weeks & surprisingly high rates of LLDAS Too early to know if useful, but worth evaluating in a phase 3 #ACR25 @RheumNow Abstr#LB01 https://t.co/oPOLG82nwi

• https://x.com/EBRheum/status/1983206373065470152/photo/1

Late breaking: secukinumab out-performs ustekinumab in PsA pt who have failed TNF therapy RCT of 119 pt 57.1% response at wk 28 in SEC 27% response at wk 28 in UST Numerically lower adverse events leading to d/c in SEC @RheumNow #ACR25 #ACRBest Abst LB06 https://t.co/wDxtscP2ku

• https://x.com/Dr_Brian_MD/status/1983206111298650538/photo/1

Serrano-Combarro et al. Baricitinib in RA-ILD. Observational, 42 patients. Progressive ILD in 26%. More frequent in women. @RheumNow #ACR25 Abstr#2229 https://t.co/ZXfgxKoau7

• https://x.com/RichardPAConway/status/1983205618925129939/photo/1

Cutaneous vasculitis: who is most likely to have systemic disease? 430 pt w skin vasculitis examined in case-control Associated with risk for systemic vasculitis/CTD: - GI sx - ulcerating/necrotic lesions - constitutional sx - hematuria @RheumNow #ACR25 Abst 2525 https://t.co/lRjLKRYxDW

• https://x.com/Dr_Brian_MD/status/1983204033729892687/photo/1

To be continued (or discontinued?): Abstract 2360: Compared to TNFi, IL-17i & JAKi users had 🔹 Higher odds of med switching <180 days 🔹 Shorter time to discontinuation @RheumNow #ACR25 #axSpA https://t.co/IOHaFSJqHn

• https://x.com/AkhilSoodMD/status/1983203353975808401/photo/1

Interesting study evaluating the "CALLY" index (serum albumin × lymphocyte count / CRP / 10,000) for predicing mortality in AAV I typically dislike these because (1) they are often cumbersome to calculate & (2) they often perform poorly This one piqued my interest; pretty https://t.co/ziroQOH5Cq

• https://x.com/EBRheum/status/1983203214729085107/photo/1

Meta-analysis of 3 RCTs (n=1990) shows IL-17i offers comparable joint response but superior skin clearance vs adalimumab in biologic-naive PsA. IL-17i also had fewer discontinuations due to adverse events. Supports sequencing of biologics through different mechanisms of action in https://t.co/SJgFUMxWVb

• https://x.com/synovialjoints/status/1983202097903370743/photo/1

RESET-RA, RCT of vagus nerve stim (device that zaps pts in neck) Marginal improvements in ACR20 at wk 12; trend in to improvement in unblinded part of study fwiw Have never seen result that is more likely to be driven by plbo effect & unblinding 🤪 @RheumNow #ACR25 Abstr#2278 https://t.co/BlR570nv7k

• https://x.com/EBRheum/status/1983201340403704312/photo/1
• https://x.com/EBRheum/status/1983201340403704312/photo/1
• https://x.com/EBRheum/status/1983201340403704312/photo/1
• https://x.com/EBRheum/status/1983201340403704312/photo/1

MSK side effects of CAR-T, based on FAERS pharmacovigilance data (also see @DrGomezPuerta in @seminarthrheum https://t.co/LnwjU5aebs) #ACR25 ABST1731 @RheumNow https://t.co/kREEy3HLE9

• https://www.sciencedirect.com/science/article/abs/pii/S0049017224002506
• https://x.com/drdavidliew/status/1983201000443072522/photo/1

PLEX continues to be OUT for DAH in AAV Retrospective review of ~1.4k AAV-DAH pt 375 who received PLEX compared to those who did not PLEX tx patients: - higher odds of death - higher sepsis - increased LOS - increased hospitalization cost @RheumNow #ACR25 Abst 2517

Mateo Faxas et al. TriNetX study, propensity score matched. 3000 patients. Arrythmia risk is higher with IL-6i vs TNFi in diabetic RA patients. V Tachy (HR 1.4), PPM need (HR 1.4) significantly higher. AF, SVT, VF all numerically increased. @RheumNow #ACR25 Abstr#2283 https://t.co/U2Tk38Mobg

• https://x.com/RichardPAConway/status/1983199326869565612/photo/1

Molina et al. 52 weeks of MANHATTAN study. Guselkumab vs second TNFi after failure 1st TNFi in PsA. MDA 52% vs 33%. Remission/LDA 67% vs 62%. @RheumNow #ACR25 Abstr#2373 https://t.co/qdtOlKLfNU

• https://x.com/RichardPAConway/status/1983197816982823217/photo/1